Open AccessReduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Author(s) -
Shawn J. Kile,
William Au,
Carol Parise,
Jaideep Sohi,
Tracy L. Yarbrough,
Alan Czeszynski,
K. O. Johnson,
Dan Redline,
Andrea Hankins,
Kimberley Rose
Publication year - 2020
Publication title -
american journal of alzheimer's disease and other dementias
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 60
eISSN - 1938-2731
pISSN - 1533-3175
DOI - 10.1177/1533317519899800
Subject(s) - amyloid (mycology) , cognitive impairment , retinal , positron emission tomography , medicine , retina , central nervous system , β amyloid , standardized uptake value , pathology , ophthalmology , alzheimer's disease , nuclear medicine , psychology , disease , neuroscience
Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.